Study of Stapokibart Injection in Patients With Allergic Rhinitis

Phase 2 Recruiting 120 enrolled Keymed Biosciences Co.Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a Randomized, Double-blind, Placebo-controlled phase II clinical study evaluating the efficacy and safety of Stapokibart injection in patients with allergic rhinitis.

Timeline

Start: 2024-09-30
Primary completion: 2025-10-30
Completion: 2025-10-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CM310	Monoclonal antibody	—	Subcutaneous

Study of Stapokibart Injection in Patients With Allergic Rhinitis

Summary

Timeline

Drugs

Indications